+

WO1998015626A3 - Mutant ciita molecule and uses thereof - Google Patents

Mutant ciita molecule and uses thereof Download PDF

Info

Publication number
WO1998015626A3
WO1998015626A3 PCT/GB1997/002751 GB9702751W WO9815626A3 WO 1998015626 A3 WO1998015626 A3 WO 1998015626A3 GB 9702751 W GB9702751 W GB 9702751W WO 9815626 A3 WO9815626 A3 WO 9815626A3
Authority
WO
WIPO (PCT)
Prior art keywords
ciita
polypeptide
useful
molecule
amino acid
Prior art date
Application number
PCT/GB1997/002751
Other languages
French (fr)
Other versions
WO1998015626A2 (en
Inventor
John William Fabre
Kenth Tomas Gustafsson
Sheng Yun
Original Assignee
Inst Of Child Health
John William Fabre
Kenth Tomas Gustafsson
Sheng Yun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620940.8A external-priority patent/GB9620940D0/en
Priority claimed from GBGB9705911.7A external-priority patent/GB9705911D0/en
Application filed by Inst Of Child Health, John William Fabre, Kenth Tomas Gustafsson, Sheng Yun filed Critical Inst Of Child Health
Priority to AU45675/97A priority Critical patent/AU4567597A/en
Publication of WO1998015626A2 publication Critical patent/WO1998015626A2/en
Publication of WO1998015626A3 publication Critical patent/WO1998015626A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A polypeptide that comprises the amino acid sequence of a class II trans activator (CIITA) protein from the N-terminus of which amino acid residues are missing such that the resulting polypeptide reduces the expression of MHC class II antigens is useful in the treatment of autoimmune disease and in the production of transgenic donor animals for xenografts and in the treatment of autoimmune diseases. Ribozymes targeting bases 1159-1161 of human CIITA are also useful, as are nucleic acids encoding the polypeptide and the ribozyme.
PCT/GB1997/002751 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof WO1998015626A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45675/97A AU4567597A (en) 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9620940.8 1996-10-08
GBGB9620940.8A GB9620940D0 (en) 1996-10-08 1996-10-08 Mutant ciita molecule and uses thereof
GBGB9705911.7A GB9705911D0 (en) 1997-03-21 1997-03-21 Mutant CIITA molecule and uses thereof
GB9705911.7 1997-03-21

Publications (2)

Publication Number Publication Date
WO1998015626A2 WO1998015626A2 (en) 1998-04-16
WO1998015626A3 true WO1998015626A3 (en) 2000-08-17

Family

ID=26310180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002751 WO1998015626A2 (en) 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof

Country Status (2)

Country Link
AU (1) AU4567597A (en)
WO (1) WO1998015626A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250118A1 (en) * 2002-07-19 2004-02-09 Genethor Gmbh Non-antigen presenting cells for selecting t cells
AU2003289907A1 (en) * 2002-11-28 2004-06-18 Genethor Gmbh Cells not presenting antigen for suppressing pathological immune reactions
US7745690B2 (en) * 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals
KR102173587B1 (en) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 Methods for treating or preventing fatigue
CN103492576A (en) * 2011-02-14 2014-01-01 雷维维科公司 Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BONTRON S ET AL: "Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.", MOLECULAR AND CELLULAR BIOLOGY, (1997 AUG) 17 (8) 4249-58., XP002055140 *
CHANG C H ET AL: "Class II transactivator ( CIITA ) is sufficient for the inducible expression of major histocompatibility complex class II genes.", JOURNAL OF EXPERIMENTAL MEDICINE, (1994 OCT 1) 180 (4) 1367-74., XP002055137 *
CHANG C H ET AL: "Mice lacking the MHC class II transactivator ( CIITA ) show tissue-specific impairment of MHC class II expression.", IMMUNITY, (1996 FEB) 4 (2) 167-78., XP002055135 *
CHIN K C ET AL: "Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 MAR 18) 94 (6) 2501-6., XP002055139 *
RILEY J L ET AL: "Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).", IMMUNITY, (1995 MAY) 2 (5) 533-43., XP002051560 *
SCHLAEGER T M ET AL: "VASCULAR ENDOTHELIAL CELL LINEAGE-SPECIFIC PROMOTER IN TRANSGENIC MICE", DEVELOPMENT, vol. 121, no. 4, 1995, pages 1089 - 1098, XP000604125 *
STEIMLE V ET AL: "Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).", CELL, (1993 OCT 8) 75 (1) 135-46., XP002051559 *
THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29, 1995 *
TOTH C R ET AL: "A dominant-negative mutant of the class II MHC transactivator CIITA.", 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, ABSTRACT BOOK PAGE 695, ABSTRACT 4124, XP002055136 *
YUN S ET AL: "Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain.", INTERNATIONAL IMMUNOLOGY 9 (10). 1545-1553., October 1997 (1997-10-01), XP002055141 *
ZHOU H ET AL: "CIITA -dependent and -independent class II MHC expression revealed by a dominant negative mutant.", JOURNAL OF IMMUNOLOGY, (1997 MAY 15) 158 (10) 4741-9., XP002055138 *
ZHOU H ET AL: "Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.", IMMUNITY, (1995 MAY) 2 (5) 545-53., XP002051590 *

Also Published As

Publication number Publication date
WO1998015626A2 (en) 1998-04-16
AU4567597A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
EP0888122A4 (en) HYBRID INTERFERON-alpha PROTEIN AND IMMUNOGLOBULIN Fc FRAGMENT PROVIDED BY NON-IMMUNOGENIC PEPTIDE
AU2001278797A1 (en) Expression vector using for animal cell
WO1995021919A3 (en) Protein having tpo activity
ATE287963T1 (en) PSEUDOMONAS EXOTOXIN - MYELIN BASIC PROTEIN CHIMERIC PROTEINS
WO2002044197A3 (en) Cytokine receptor binding peptides
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO1998015626A3 (en) Mutant ciita molecule and uses thereof
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
RU2214273C2 (en) Dna-sequences encoding human proteins tx and ty relates to enzyme converting interleukin-1-beta
WO1997016549A3 (en) Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands
AU692213B2 (en) Equine arteritis virus peptides, antibodies and their use in a diagnostic test
EE200000478A (en) Peptide, gene encoding it, diagnostic reagent and diagnostic kit, for use in the treatment of rickettsia
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
WO2002016589A3 (en) Human abc transporter family member and uses thereof
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE68914397D1 (en) Human lymphotoxin.
EP1225182A3 (en) Human phospholipid transporter
EP0723016A3 (en) Activating factor of leukocytes
Jorgensen et al. Growth hormone therapy.
EP1264843A3 (en) 38554, 57301 and 58324, Human organic ion transporters and uses therefor
WO2002026958A3 (en) Human neprilysin protease
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof
WO2002018439A3 (en) 52991, a human transporter protein and uses therefor
WO2002029041A3 (en) 32146 and 57259, novel human transporters and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998517308

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载